US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

OncoVista Innovative Therapies, Inc.

0.0001

+0.0000

Volume:- -

Turnover:- -

Market Cap:2.36K

PE:0.00

High:0.0001

Open:0.0001

Low:0.0001

Close:0.0001

Loading ...

Overview Company News Filings

Company Profile

Company Name:

OncoVista Innovative Therapies, Inc.

Exchange:

EXPERT

Establishment Date:

2004

Employees:

2

Office Location:

14785 Omicron Drive,Suite 104,San Antonio,Texas,United States

Website:

http://www.oncovista.com

Zip Code:

78245

Phone:

Fax:

- -

Introduction:

OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/OVIT/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"OVIT","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OVIT\",,,,,undefined,":{"symbol":"OVIT","market":"US","secType":"STK","nameCN":"OncoVista Innovative Therapies, Inc.","latestPrice":0.0001,"timestamp":1743536460000,"preClose":0.0001,"halted":0,"volume":0,"delay":15,"floatShares":0,"shares":23558530,"eps":-0.147293,"marketStatus":"Trading","change":0,"latestTime":"04-01 15:41:00 EDT Delay","open":0.0001,"high":0.0001,"low":0.0001,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.147293,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1743537600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"EXPERT","adjPreClose":0.0001,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"OVIT\",,,,,undefined,":{"symbol":"OVIT","floatShares":0,"roa":"-2357.68%","roe":"61.23%","lyrEps":-0.117518,"shares":23558530,"dividePrice":0,"high":0.0001,"amplitude":0,"preClose":0.0001,"low":0.0001,"week52Low":0.000001,"pbRate":"-0.00","week52High":0.0002,"institutionHeld":0,"latestPrice":0.0001,"eps":-0.147293,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.147293,"open":0.0001,"prevYearClose":0.0002,"prevWeekClose":0.0001,"prevMonthClose":0.0001,"prevQuarterClose":0.0001,"fiveDayClose":0.0001,"twentyDayClose":0.0002,"sixtyDayClose":0.0002},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{"companyId":26079298,"yearFounded":2004,"employeeNum":2,"address":"14785 Omicron Drive,Suite 104,San Antonio,Texas,United States","zipCode":"78245","officePhone":"210-677-6000"},"stockCompanyDetail":{"websiteUrl":"http://www.oncovista.com","stockEarnings":[{"period":"1week","weight":0.2438},{"period":"1month","weight":-0.2684},{"period":"3month","weight":-0.2764},{"period":"6month","weight":0.0757},{"period":"1year","weight":-0.2064},{"period":"ytd","weight":-0.5578}],"description":"OncoVista Innovative Therapies, Inc., a biopharmaceutical company, develops targeted anticancer therapies by utilizing tumor-associated biomarkers. The company's product candidates include Cordycepin (OVI-123), which is in Phase I/II clinical trials for the treatment of refractory TdT positive leukemias; and L-Nucleoside Conjugates (OVI-117) that is under pre-clinical development for the treatment of colon cancer. The company was founded in 2004 and is based in San Antonio, Texas.","exchange":"EXPERT","name":"OncoVista Innovative Therapies, Inc.","nameEN":"OncoVista Innovative Therapies, Inc."}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"OVIT\",market:\"US\",,,undefined,":null,"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/OVIT\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"OVIT\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"OVIT\",market:\"US\",delay:false,,,undefined,":{}}}